跳至主導覽
跳至搜尋
跳過主要內容
國立陽明交通大學研發優勢分析平台 首頁
English
中文
在 國立陽明交通大學研發優勢分析平台 搜尋內容
首頁
人員
單位
研究成果
計畫
獎項
活動
貴重儀器
影響
ABL genomic editing sufficiently abolishes oncogenesis of human chronic myeloid leukemia cells in vitro and in vivo
Shu Huey Chen
, Yao Yu Hsieh
, Huey En Tzeng
,
Chun-Yu Lin
, Kai Wen Hsu
, Yun Shan Chiang
, Su Mei Lin
, Ming Jang Su
, Wen Shyang Hsieh
, Chia Hwa Lee
*
*
此作品的通信作者
生物資訊及系統生物研究所
研究成果
›
同行評審
24
引文 斯高帕斯(Scopus)
總覽
指紋
指紋
深入研究「ABL genomic editing sufficiently abolishes oncogenesis of human chronic myeloid leukemia cells in vitro and in vivo」主題。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Keyphrases
Oncogenesis
100%
Chronic Myeloid Leukemia
100%
Myeloid Leukemia Cells
100%
Genome Editing
100%
Virus
83%
Leukemia Patients
66%
Gene-edited
66%
Chronic Myelogenous Leukemia Cells
33%
BCR-ABL
33%
Imatinib
33%
BCR-ABL Fusion Gene
33%
Indel
33%
K562 Cells
33%
Single Guide RNA (sgRNA)
33%
Leukemia
33%
Gene Editing
33%
Clinical Application
16%
Junction Region
16%
Cell Growth
16%
Clinical Samples
16%
Treatment Efficacy
16%
Safety Efficacy
16%
Cancer Cell Death
16%
Protein Expression
16%
Cell Population
16%
Infected Cells
16%
Cell Apoptosis
16%
Cell Survival
16%
Bioluminescence Imaging
16%
Tumorigenicity
16%
Cas9 Protein
16%
Most Common Form
16%
Off-target Effects
16%
User Safety
16%
Optimal Response
16%
Cancer Cell Growth
16%
Xenograft Mouse Model
16%
K562
16%
Leukemia Cells
16%
Remission Rate
16%
Bone Marrow Cells
16%
Significant Cancer
16%
BCR-ABL Inhibitors
16%
Cell Suppression
16%
Philadelphia Chromosome
16%
Medicine and Dentistry
In Vitro
100%
Carcinogenesis
100%
Chronic Myelogenous Leukemia
100%
Leukemia Cell
100%
Virus
62%
Indel Mutation
25%
Imatinib
25%
Leukemia
25%
K562 Cells
25%
Infection
12%
Xenograft
12%
Cell Growth
12%
Cancer Cell
12%
Cancer Growth
12%
Protein Expression
12%
Cell Survival
12%
Programmed Cell Death
12%
Combination Therapy
12%
Carcinogenicity
12%
Phosphotransferase Inhibitor
12%
Cell Population
12%
Cell Death
12%
Cas9
12%
Clustered Regularly Interspaced Short Palindromic Repeat
12%
Spontaneous Remission
12%
BCR ABL Protein
12%
Philadelphia 1 Chromosome
12%
Oncoprotein
12%
Bioluminescence
12%
Bone Marrow Cell
12%
Biochemistry, Genetics and Molecular Biology
Carcinogenesis
100%
Myeloid
100%
ABL (Gene)
100%
Genomics
100%
Cancer Cell
28%
Cell Growth
28%
Indel
28%
K562 Cells
28%
Genome Editing
28%
Imatinib
28%
Cell Survival
14%
Cell Death
14%
Phosphotransferase
14%
Kinase
14%
Protein Expression
14%
Mouse Model
14%
CRISPR/Cas9
14%
Bioluminescence Imaging
14%
Philadelphia Chromosome
14%
Programmed Cell Death
14%
Pharmacology, Toxicology and Pharmaceutical Science
Carcinogenesis
100%
Chronic Myeloid Leukemia
100%
Leukemia
37%
Imatinib
25%
Infection
12%
Malignant Neoplasm
12%
Mouse Model
12%
Combination Therapy
12%
Cancer Growth
12%
Phosphotransferase Inhibitor
12%
Carcinogenicity
12%
BCR ABL Protein
12%
Remission
12%
Philadelphia 1 Chromosome
12%
Oncoprotein
12%